Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fem21 is a multi-ingredient women's health nutraceutical developed by Lifestart Naturopathics as a powdered oral supplement formulated from 21 herbs, botanicals, probiotics, and superfood ingredients. Based on the provided context, it is marketed to support hormonal balance and symptoms associated with PMS, dysmenorrhea, hormonal acne, irregular periods, endometriosis, menopausal symptoms, PCOS, and fertility concerns. Its proposed activity is nonspecific and systems-oriented rather than based on a single defined molecular target, with claimed support for endocrine function involving the ovaries, adrenal glands, and thyroid, as well as estrogen metabolism, progesterone production, liver function, and digestive health. Fem21 is therefore better characterized as a branded composite nutraceutical product rather than a pharmaceutical drug with a single active ingredient or well-validated target-specific mechanism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fem21.